BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NovoCure Ltd. Release: Clinical Trial for Newly Diagnosed Glioblastoma Opened in Korea


5/7/2013 9:07:28 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ST. HELIER, Jersey, May 7, 2013 /PRNewswire/ -- Novocure announced today that the EF-14 pivotal clinical trial for patients with newly diagnosed glioblastoma (GBM) brain tumors has enrolled its first patient in Korea. This randomized, controlled trial is designed to enroll approximately 700 patients and will test the efficacy and safety of NovoTTF(TM) Therapy when added to the current best standard of care for newly diagnosed GBM.

NovoTTF Therapy is delivered by a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device, the NovoTTF-100A System, has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The device inhibits mitosis by creating a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.

"Newly diagnosed GBM patients in the United States, Europe and Asia may now enroll in the EF-14 Clinical Trial, underscoring Novocure's commitment to providing global access to NovoTTF(TM) Therapy." said Eilon Kirson, M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development, "We look forward to working with our principal investigators in Korea to enroll EF-14."

The EF-14 clinical trial is designed to evaluate potential benefits of NovoTTF Therapy when given as a concurrent therapy with standard of care temozolomide chemotherapy. The trial is currently enrolling patients at more than 70 hospitals around the world, and will include nine centers in Korea. The opening of the trial in Korea followed a full review of the clinical trial protocol and device by the Korea Food and Drug Administration (KFDA).

About NovoTTF Therapy and the NovoTTF-100A System

NovoTTF Therapy is delivered by a portable, non-invasive medical device designed for continuous use throughout the day by the patient. The device, the NovoTTF-100A System, has been shown in vitro and in vivo to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate. The delivery system weighs about six pounds and creates a low intensity, alternating electric field within a tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division. The device is an investigational device in the United States for patients with newly diagnosed glioblastoma and has not been approved by the FDA for sale in this indication.

About Novocure(TM)

Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors. Novocure's US operations are based in New York, NY and Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES